Tags

Type your tag names separated by a space and hit enter

Peripheral neuropathy in prediabetes and the metabolic syndrome.
J Diabetes Investig 2017; 8(5):646-655JD

Abstract

Peripheral neuropathy is a major cause of disability worldwide. Diabetes is the most common cause of neuropathy, accounting for 50% of cases. Over half of people with diabetes develop neuropathy, and diabetic peripheral neuropathy (DPN) is a major cause of reduced quality of life due to pain, sensory loss, gait instability, fall-related injury, and foot ulceration and amputation. Most patients with non-diabetic neuropathy have cryptogenic sensory peripheral neuropathy (CSPN). A growing body of literature links prediabetes, obesity and metabolic syndrome to the risk of both DPN and CSPN. This association might be particularly strong in type 2 diabetes patients. There are no effective medical treatments for CSPN or DPN, and aggressive glycemic control is an effective approach to neuropathy risk reduction only in type 1 diabetes. Several studies suggest lifestyle-based treatments that integrate dietary counseling with exercise might be a promising therapeutic approach to early DPN in type 2 diabetes and CSPN associated with prediabetes, obesity and metabolic syndrome.

Authors+Show Affiliations

Department of Neurology, Division of Neuromuscular Medicine, Ohio State University, Columbus, Ohio, USA.Department of Neurology, Division of Neuromuscular Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28267267

Citation

Stino, Amro M., and Albert G. Smith. "Peripheral Neuropathy in Prediabetes and the Metabolic Syndrome." Journal of Diabetes Investigation, vol. 8, no. 5, 2017, pp. 646-655.
Stino AM, Smith AG. Peripheral neuropathy in prediabetes and the metabolic syndrome. J Diabetes Investig. 2017;8(5):646-655.
Stino, A. M., & Smith, A. G. (2017). Peripheral neuropathy in prediabetes and the metabolic syndrome. Journal of Diabetes Investigation, 8(5), pp. 646-655. doi:10.1111/jdi.12650.
Stino AM, Smith AG. Peripheral Neuropathy in Prediabetes and the Metabolic Syndrome. J Diabetes Investig. 2017;8(5):646-655. PubMed PMID: 28267267.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Peripheral neuropathy in prediabetes and the metabolic syndrome. AU - Stino,Amro M, AU - Smith,Albert G, Y1 - 2017/05/03/ PY - 2017/01/05/received PY - 2017/02/25/revised PY - 2017/02/27/accepted PY - 2017/3/8/pubmed PY - 2018/5/9/medline PY - 2017/3/8/entrez KW - Metabolic syndrome KW - Peripheral neuropathy KW - Prediabetes SP - 646 EP - 655 JF - Journal of diabetes investigation JO - J Diabetes Investig VL - 8 IS - 5 N2 - Peripheral neuropathy is a major cause of disability worldwide. Diabetes is the most common cause of neuropathy, accounting for 50% of cases. Over half of people with diabetes develop neuropathy, and diabetic peripheral neuropathy (DPN) is a major cause of reduced quality of life due to pain, sensory loss, gait instability, fall-related injury, and foot ulceration and amputation. Most patients with non-diabetic neuropathy have cryptogenic sensory peripheral neuropathy (CSPN). A growing body of literature links prediabetes, obesity and metabolic syndrome to the risk of both DPN and CSPN. This association might be particularly strong in type 2 diabetes patients. There are no effective medical treatments for CSPN or DPN, and aggressive glycemic control is an effective approach to neuropathy risk reduction only in type 1 diabetes. Several studies suggest lifestyle-based treatments that integrate dietary counseling with exercise might be a promising therapeutic approach to early DPN in type 2 diabetes and CSPN associated with prediabetes, obesity and metabolic syndrome. SN - 2040-1124 UR - https://www.unboundmedicine.com/medline/citation/28267267/Peripheral_neuropathy_in_prediabetes_and_the_metabolic_syndrome_ L2 - https://doi.org/10.1111/jdi.12650 DB - PRIME DP - Unbound Medicine ER -